This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Triact Therapeutics, Inc.. Active years: 2014-2016.
Company Filing History:
Years Active: 2014-2016
Title: Dan Hoth: Innovator in Cancer Therapy
Introduction
Dan Hoth is a notable inventor based in San Francisco, CA (US). He has made significant contributions to the field of cancer therapy, holding 2 patents that focus on innovative treatment methods for proliferative disorders. His work is characterized by a commitment to improving patient outcomes through advanced pharmaceutical compositions.
Latest Patents
Hoth's latest patents include groundbreaking research on cancer therapy. One patent discusses compositions and methods for treating a proliferative disorder by administering a pharmaceutical composition of a dual kinase inhibitor. Specifically, catecholic butanes are identified as potential dual kinase inhibitors. This treatment is particularly relevant for patients who have previously been treated with Tarceva or other therapeutic compounds and have either relapsed or developed resistance to treatment. The compounds may exhibit a synergistic effect when administered alongside another agent.
Another patent by Hoth also focuses on catecholic butanes for cancer therapy. This application outlines methods for treating proliferative disorders and emphasizes the importance of co-administering an EGFR inhibitor. Additionally, it involves analyzing samples for levels of IGF-1R and EGFR, allowing for a comparative assessment against control levels. Patients can be selected for treatment based on these assessments, with options for further treatment using EGFR inhibitors, IGF-1R inhibitors, or both.
Career Highlights
Dan Hoth is currently associated with Triact Therapeutics, Inc., where he continues to develop innovative solutions in cancer treatment. His work is instrumental in advancing therapeutic options for patients facing challenging diagnoses.
Collaborations
Hoth collaborates with esteemed colleagues such as Thomas F. White and Edward F. Schnipper, contributing to a dynamic research environment focused on cancer therapies.
Conclusion
Dan Hoth's contributions to cancer therapy through his patents and collaborative efforts highlight his dedication to improving treatment options for patients. His innovative approaches in utilizing dual kinase inhibitors represent a significant advancement in the field.